Skip to content
Search

Latest Stories

India's Wockhardt will supply millions of doses of Covid-19 vaccines to UK

INDIAN drugmaker Wockhardt Ltd has said it will supply millions of doses of multiple Covid-19 vaccines to the UK, including the one being developed by AstraZeneca and Oxford University.

The company has dedicated a fill-and-finish capacity -- the final manufacturing step of putting vaccines into vials or syringes and packaging them -- as part of an agreement with the UK government, it said on Monday (3).


The UK government has also reserved one fill-and-finish production line at a Wockhardt subsidiary in Wrexham, Wales, for its exclusive use for the next 18 months to secure supply.

Commenting on the development, Business Secretary Alok Sharma said: “Ensuring the UK has the capability to research, develop and manufacture a safe and effective vaccine is critical in our fight against coronavirus.

"Today we have secured additional capacity to manufacture millions of doses of multiple Covid-19 candidates, guaranteeing the supply of vaccines we need to protect people across the UK rapidly and in large numbers."

Dr Habil Khorakiwala, founder chairman of Wockhardt, said: "The arrangement brings in a huge sense of purpose and pride -- it upholds our ongoing commitment to fight against such a pandemic of global human importance. As a global organisation, we are focused and committed to assist in mitigating the worldwide impact of Covid-19."

Currently, more than 150 vaccines are being developed and tested around the world to stop the pandemic, with 25 in human clinical trials, according to the World Health Organization.

Kate Bingham, chair of UK Vaccines Task Force, said: "Never before have we needed to find and manufacture a vaccine at this speed and scale in order to protect the UK population.

"The agreement with Wockhardt will boost our capability to ensure that from the moment a successful vaccine is identified we will be able to produce the quantities of vaccine required, as quickly as possible, for the people who need it."

Ravi Limaye, managing director of Wockhardt UK, said the company was "immensely proud" in "taking a lead role in the nation’s fight" against the pandemic.

"We expect to start delivering the first doses of the vaccine later this year," he added.

More For You

NHS cancer detection is stuck at 55 per cent. Here's why

Government targets 75 per cent early cancer detection by 2035, but Cancer Research UK says progress is falling short

Getty Images

NHS cancer detection is stuck at 55 per cent. Here's why

Highlights

  • One cancer diagnosis every 80 seconds in UK.
  • Early detection unchanged since 2013.
  • 107,000 patients wait over two months for treatment.
The NHS is not catching cancers any earlier than it did ten years ago. While 403,000 people now get a cancer diagnosis each year, the proportion caught at early stages stays around 55 per cent, barely changed from 54 per cent in 2013.

Cancer Research UK's latest report shows the detection system is not working well enough.

Michelle Mitchell, the charity's chief executive, called the findings "deeply worrying" and warned that "without urgent action, we won't see rates of improvements in cancer survival and outcomes that cancer patients deserve and expect."

Keep ReadingShow less